Zoetis Inc - Class A

NYSE: ZTS
$193.24
-$3.24 (-1.6%)
Closing Price on September 19, 2024

ZTS Articles

The top analyst upgrades, downgrades and initiations seen from Wednesday include AT&T, CenturyLink, MercadoLibre, Netflix, Starbucks, Tiffany, TJX Companies and YRC Worldwide.
The top analyst upgrades, downgrades and initiations seen from Tuesday include Alliance Data Systems, Blackstone, Cognizant Technology Solutions, HCA, Paychex, Salesforce,com, Wynn Resorts, Yext and...
Analysts at Jefferies have come up with a list of four pharmaceuticals stocks that may be good investments for a time of uncertainty in global markets.
Abaxis shares hit an all-time high early on Wednesday after it was announced that Zoetis would be acquiring the firm.
Here are the 10 stocks that now make up the Merrill Lynch Growth 10 portfolio, including new additions Netflix and D.R. Horton.
The top analyst upgrades, downgrades and other research calls from Tuesday include Cheniere Energy, Consolidated Edison, Foot Locker, Shopify, Tesla, Veeco Instruments and Zoetis.
The top analyst upgrades, downgrades and other research calls on Tuesday include Ambarella, BlackBerry, Schlumberger, Valero Energy, Whiting Petroleum and Zynga.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now...
These four new additions to Stifel's Select List are all rated Buy and make good sense for growth investors looking for new ideas.
Thursday’s top analyst upgrades, downgrades and initiations include Advanced Micro Devices, Comerica, General Mills, Mastercard and Vertex Pharmaceuticals.
Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds boosted their equity positions by nearly 3% in the third quarter.
Now is a good time to add quality stocks in front of what is usually a very good time of the year for equities. These four stocks offer investors solid upside potential.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
A recent Merrill Lynch research report features the firm's top ideas for the fourth quarter. These eight stocks look like outstanding picks for growth stock accounts.
If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a report on the state of animal health, with two Buy...